Literature DB >> 3816961

Further evaluation of the mechanism by which amphetamine reduces striatal dopamine metabolism: a brain dialysis study.

T Zetterström, T Sharp, U Ungerstedt.   

Abstract

An intracerebral dialysis method was used in the halothane-anaesthetized rat to further clarify the site which mediates the amphetamine-induced decrease of the striatal dopamine (DA) metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Following subcutaneous injection of amphetamine (0.1-5.0 mg/kg), DOPAC and HVA in striatal perfusates decreased over the 2 h time course, with 0.5 mg/kg of the drug having maximal effect. In comparison, amphetamine (0.1-5.0 mg/kg) caused a strictly dose-dependent increase of DA in striatal perfusates. Following low (0.1-5.0 mg/kg) but not high (2.0-5.0 mg/kg) doses of amphetamine there was a negative correlation between the increase of DA and decrease of DOPAC in the striatum. Amphetamine (0.5 mg/kg) caused a reduction in DA metabolism in the ibotenic acid-lesioned striatum. Intranigral injection of 10 micrograms, but not of 1 microgram amphetamine, decreased DOPAC (-27%) in the striatal perfusates. However, injection of 1 microgram amphetamine into the striatum caused a strong decrease in striatal DOPAC (-46%) and HVA (-22%). The possible mechanisms of action of amphetamine are discussed in the light of these data.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816961     DOI: 10.1016/0014-2999(86)90002-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Effect of transient reduction of cerebral blood flow in normotensive rats on striatal dopamine-release.

Authors:  S Läer; F Block; G Huether; C Heim; K H Sontag
Journal:  J Neural Transm Gen Sect       Date:  1993

2.  Effects of chronic electroconvulsive shock on interstitial concentrations of dopamine in the nucleus accumbens.

Authors:  G G Nomikos; A P Zis; G Damsma; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  In vivo neurochemical characterization of anatoxin-a evoked dopamine release from striatum.

Authors:  F Campos; R Durán; L Vidal; L R F Faro; M Alfonso
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

4.  Glutamate and GABA modulate dopamine in the pedunculopontine tegmental nucleus.

Authors:  Björn Steiniger; Beate D Kretschmer
Journal:  Exp Brain Res       Date:  2003-02-26       Impact factor: 1.972

5.  Isolation rearing impairs the reinforcing efficacy of intravenous cocaine or intra-accumbens d-amphetamine: impaired response to intra-accumbens D1 and D2/D3 dopamine receptor antagonists.

Authors:  G D Phillips; S R Howes; R B Whitelaw; T W Robbins; B J Everitt
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

6.  Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.

Authors:  I Lamensdorf; S Porat; R Simantov; J P Finberg
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

7.  On the mechanism of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats.

Authors:  M Miele; M A Mura; P Enrico; G Esposito; P A Serra; R Migheli; D Zangani; E Miele; M S Desole
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

8.  Specific effects by the psychotomimetic drugsd-amphetamine and phencyclidine on the performance of an aversely motivated successive visual discrimination in the rat.

Authors:  S Ahlenius; E Ericson; T H Svensson
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

9.  Behavioral activation in rats requires endogenous ascorbate release in striatum.

Authors:  G V Rebec; Z Wang
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

10.  Influence of naloxone upon motor activity induced by psychomotor stimulant drugs.

Authors:  D N Jones; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.